Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Looks At OTC Loperamide Packaging To Curb Opioid-Related Abuse

Executive Summary

Ingredient in J&J's Imodium and numerous OTC generics acts on opioid receptors in the gut to slow movement in the intestines and decrease bowel movements, but dosing at much higher than recommended amounts can lead to serious problems including severe heart rhythm problems and death.


Related Content

Smaller OTC Loperamide Packages Wait As Retailers Limit Purchase Amounts
US FDA Chief Gottlieb Envisions Tiered Mandates For Opioid Training System
State Opioid Prescribing Databases Can Handle US FDA's Needs, Officials Say
Opioid REMS Revisions Reflect Some, Not All, Stakeholder Concerns
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Nonprofit Pharma Targets Making Naloxone Available OTC, Trimming Price
Making Imodium Rx-Only No Help On Curbing Opioid Abuse – CHPA
Loperamide Abuse Triggers Look At Potential Label Warning


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts